Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML: Results of a Phase 1 Study

被引：5

作者：

Altman, Jessica K. ^{[1
]}

Bhatnagar, Bhavana ^{[2
]}

Abedin, Sameem ^{[3
]}

Przespolewski, Amanda ^{[4
]}

Patel, Prapti A. ^{[5
]}

Schiller, Gary J. ^{[6
]}

Gill, Stanley ^{[7
]}

Patel, Dhruva ^{[7
]}

Fan, Linyi ^{[7
]}

Tiu, Ramon V. ^{[7
]}

Strickland, Stephen A. ^{[8
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA

[3] Med Coll Wisconsin, Dept Med, Blood & Marrow Transplantat & Cellular Therapy Pr, Div Hematol & Oncol, Milwaukee, WI 53226 USA

[4] Roswell Pk Comprehens Canc Ctr, Leukemia Serv, Dept Med, Buffalo, NY USA

[5] Univ Texas Southwestern Med Ctr Dallas, Dept Med Oncol, Dallas, TX 75390 USA

[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[7] Astellas Pharma Global Dev, Northbrook, IL USA

[8] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

关键词：

D O I：

10.1182/blood-2021-150707

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2343

引用

页数：6